Neuropeptides and appetite control
- 30 July 2002
- journal article
- review article
- Published by Wiley in Diabetic Medicine
- Vol. 19 (8), 619-627
- https://doi.org/10.1046/j.1464-5491.2002.00790.x
Abstract
Obesity is important in the aetiology of type 2 diabetes, and presents a major barrier to its successful prevention and management. Obesity develops when energy intake exceeds energy expenditure over time. A complex system has evolved to maintain energy homeostasis, but this is biased towards weight gain. Meal size is controlled by a series of short‐term hormonal and neural signals that derive from the gastrointestinal tract, such as cholecystokinin whereas others may initiate meals, such as the recently discovered hormone, ghrelin. Other hormones such as insulin and leptin, together with circulating nutrients, indicate long‐term energy stores. All these signals act at several central nervous system (CNS) sites but the pathways converge on the hypothalamus, which contains a large number of peptide and other neurotransmitters that influence food intake. As energy deficit is most likely to compromise survival, it is not surprising that the most powerful of these pathways are those that increase food intake and decrease energy expenditure when stores are depleted. When energy stores are low, production of leptin from adipose tissue, and thus circulating leptin concentrations fall, leading to increased production of hypothalamic neurotransmitters that strongly increase food intake, such as neuropeptide Y (NPY), galanin and agouti‐related protein (AGRP) and decreased levels of α‐melanocyte‐stimulating hormone (α‐MSH), cocaine and amphetamine‐regulated transcript (CART) and neurotensin that reduce food intake and increase energy expenditure. The finding that mutations in leptin and POMC lead to severe early onset obesity in bumans has highlighted the importance of these peptides in humans. This new understanding may eventually lead to new treatments for obesity that will be of particular benefit in the prevention and treatment of type 2 diabetes. Diabet. Med. 19, 619–627 (2002)Keywords
This publication has 80 references indexed in Scilit:
- Insulin modulates leptin‐induced STAT3 activation in rat hypothalamusFEBS Letters, 2001
- Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin DeficiencyNew England Journal of Medicine, 1999
- Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide YBritish Journal of Pharmacology, 1997
- Identification of targets of leptin action in rat hypothalamus.JCI Insight, 1996
- A role for glucagon-like peptide-1 in the central regulation of feedingNature, 1996
- Competitive antagonism of nitric oxide synthetase causes weight loss in miceLife Sciences, 1992
- Evidence that nitric oxide modulates food intake in miceLife Sciences, 1991
- Role of Adrenal Glands in the Development of Abnormal Glucose and Insulin Homeostasis in Genetically Obese (ob/ob) MiceHormone and Metabolic Research, 1986
- Neuropeptide Y Distribution in the Rat BrainScience, 1983
- Cholecystokinin decreases food intake in rats.Journal of Comparative and Physiological Psychology, 1973